In Brief: Vitamix Expands, No “Probiotic” In E.U. Ads, Mylan Misses On Meda, Akorn Hits On VersaPharm
This article was originally published in The Tan Sheet
Executive Summary
Vitamix triples manufacturing space; using ‘probiotic’ not allowed in E.U.; Meda rejects Mylan bids; Akorn acquires VersaPharm; La. blocks DXM sales to minors; and more news In Brief.
You may also be interested in...
Hi-Tech Deal Broadens Akorn Consumer Business
Akorn’s $650 million acquisition of Hi-Tech Pharmacal provides a potential long-term platform for Rx-to-OTC switches and offers additional OTC cross-selling opportunities with retailers. Akorn CEO Raj Rai calls the transaction a “transformative event” that will be instantly accretive for the firm.
Antula Acquisition Expands Meda's OTC Portfolio, Marketing Expertise
Meda's acquisition of fast-growing Swedish OTC firm Antula Healthcare brings on board "proven" marketing expertise to boost existing product sales, a well-established nonprescription drug portfolio and a prolific pipeline for long-term growth.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.